CTXR vs. COYA, SCTL, OPTN, IMUX, RPTX, ADAG, NVCT, VTGN, CTMX, and ELYM
Should you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include Coya Therapeutics (COYA), Societal CDMO (SCTL), OptiNose (OPTN), Immunic (IMUX), Repare Therapeutics (RPTX), Adagene (ADAG), Nuvectis Pharma (NVCT), Vistagen Therapeutics (VTGN), CytomX Therapeutics (CTMX), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical preparations" industry.
Coya Therapeutics (NASDAQ:COYA) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings, institutional ownership and community ranking.
Coya Therapeutics' return on equity of -41.63% beat Citius Pharmaceuticals' return on equity.
Coya Therapeutics has higher revenue and earnings than Citius Pharmaceuticals. Coya Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Coya Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500.
39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 12.0% of Coya Therapeutics shares are owned by company insiders. Comparatively, 15.0% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Citius Pharmaceuticals received 200 more outperform votes than Coya Therapeutics when rated by MarketBeat users. However, 85.71% of users gave Coya Therapeutics an outperform vote while only 62.05% of users gave Citius Pharmaceuticals an outperform vote.
Coya Therapeutics currently has a consensus price target of $14.00, indicating a potential upside of 62.22%. Citius Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 503.59%. Given Coya Therapeutics' higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Coya Therapeutics.
In the previous week, Coya Therapeutics had 1 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 3 mentions for Coya Therapeutics and 2 mentions for Citius Pharmaceuticals. Citius Pharmaceuticals' average media sentiment score of 0.22 beat Coya Therapeutics' score of -1.00 indicating that Coya Therapeutics is being referred to more favorably in the media.
Summary
Citius Pharmaceuticals beats Coya Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Citius Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Citius Pharmaceuticals Competitors List
Related Companies and Tools
